These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22464456)

  • 21. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
    Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
    MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
    Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
    Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.
    Richardson CM; Nunns CL; Williamson DS; Parratt MJ; Dokurno P; Howes R; Borgognoni J; Drysdale MJ; Finch H; Hubbard RE; Jackson PS; Kierstan P; Lentzen G; Moore JD; Murray JB; Simmonite H; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3880-5. PubMed ID: 17570665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.
    Norman RA; Schott AK; Andrews DM; Breed J; Foote KM; Garner AP; Ogg D; Orme JP; Pink JH; Roberts K; Rudge DA; Thomas AP; Leach AG
    J Med Chem; 2012 Jun; 55(11):5003-12. PubMed ID: 22612866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
    Ahn YM; Clare M; Ensinger CL; Hood MM; Lord JW; Lu WP; Miller DF; Patt WC; Smith BD; Vogeti L; Kaufman MD; Petillo PA; Wise SC; Abendroth J; Chun L; Clark R; Feese M; Kim H; Stewart L; Flynn DL
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5793-8. PubMed ID: 20800479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
    Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.
    Bhattacharya SK; Aspnes GE; Bagley SW; Boehm M; Brosius AD; Buckbinder L; Chang JS; Dibrino J; Eng H; Frederick KS; Griffith DA; Griffor MC; Guimarães CR; Guzman-Perez A; Han S; Kalgutkar AS; Klug-McLeod J; Garcia-Irizarry C; Li J; Lippa B; Price DA; Southers JA; Walker DP; Wei L; Xiao J; Zawistoski MP; Zhao X
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7523-9. PubMed ID: 23153798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
    Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
    Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
    Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
    J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
    Wang X; Xue G; Pan Z
    Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
    Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
    J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
    Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
    SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
    Caballero J; Alzate-Morales JH; Vergara-Jaque A
    J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
    Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.